Ixico (IXI.L) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $18.3M

Market Cap: $19.8MFounded: 2004HQ: London, United Kingdom

Sector Ranking#36 in AI / Machine Learning #135 in Diagnostics & Precision Medicine

Overview

IXICO is a mission-driven technology and services company focused on advancing precision medicine in neurology. With a 20-year track record, it has established itself as a leading provider of AI-powered neuroimaging analytics for clinical trials, helping pharmaceutical partners demonstrate drug efficacy through quantifiable brain biomarkers. Its strategy centers on the continuous enhancement of its proprietary IXI™ platform and expansion of its therapeutic expertise to capitalize on the growing demand for objective endpoints in central nervous system (CNS) drug development.

Alzheimer's Disease (AD)Huntington's Disease (HD)Parkinson's Disease (PD)Multiple Sclerosis (MS)Other Rare Neurological Diseases

Technology Platform

IXI™ is a proprietary, AI-enabled neuroimaging technology platform purpose-built for end-to-end clinical trial management and the precision analysis of imaging biomarkers in neurological disease research.

Funding History

2

Total raised:$18.3M

IPO$12.8MN+1 SingerOct 3, 2014

Series A$5.5MAlbion VenturesApr 15, 2012

Opportunities

The growing pipeline of neurological drug candidates and a regulatory shift towards objective biomarker endpoints are expanding the addressable market for IXICO's specialized services.

Its proprietary IXI™ platform positions it to capture demand for AI-driven analytics that can de-risk costly clinical trials.

Risk Factors

Revenue is dependent on biopharma R&D spending cycles and subject to client concentration risk.

Competitive pressure from larger CROs and the need to continuously innovate its technology platform present ongoing execution challenges.

Competitive Landscape

IXICO competes with large, full-service CROs with imaging divisions and other specialized imaging CROs. Its differentiation lies in its deep neurological focus, proprietary AI platform (IXI™), and 20-year track record as a pure-play neuroimaging iCRO.